HighTide Therapeutics has strengthened its leadership team with the appointment of Dr Filip Surmont as Chief Medical Officer, a move widely viewed as a strong signal of the company’s clinical and strategic ambitions in the fast-evolving cardiorenal metabolic (CKM) space.

Dr Surmont brings more than three decades of experience at global pharmaceutical leaders, including Pfizer, AstraZeneca, and Wyeth. He played a key role in the development strategy for dapagliflozin, a leading SGLT-2 inhibitor that has become a global blockbuster in the treatment of metabolic diseases.

His appointment follows encouraging clinical progress for HighTide’s lead asset, HTD1801. In a Phase III trial involving type 2 diabetes patients with mild renal impairment, the oral anti-inflammatory and metabolic modulator demonstrated superior outcomes to dapagliflozin across multiple cardiovascular, renal, and metabolic endpoints. Notably, the study showed a positive annualised eGFR slope, a rare signal that suggests potential early reversal of kidney function decline.

HTD1801 operates through a dual mechanism activating AMPK and inhibiting the NLRP3 inflammasome, targeting both metabolic dysfunction and chronic inflammation, key drivers of chronic kidney disease (CKD). This differentiated approach positions the drug as a potential next-generation therapy in a field where current standards primarily slow, rather than reverse, disease progression.

The development comes amid rising global investment in CKD therapeutics, with major pharmaceutical companies actively pursuing novel assets to address remaining unmet needs. Despite advances from SGLT-2 inhibitors and GLP-1 receptor agonists, significant residual risk persists, underscoring demand for innovative mechanisms.

With ongoing studies to validate HTD1801’s broader application in non-diabetic CKD, HighTide is advancing a holistic CKM treatment paradigm—shifting focus from late-stage intervention to early prevention and potential disease modification.